Century Therapeutics (IPSC) Research & Development (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Research & Development of $17.1 million for Q1 2026, down 35.65% year-over-year from $26.6 million in Q1 2025, and down 13.15% quarter-over-quarter from $19.7 million in Q4 2025.
Century Therapeutics (IPSC) Research & Development (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Research & Development for 7 consecutive years, with $17.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 35.65% year-over-year to $17.1 million; the TTM figure through Mar 2026 stood at $63.7 million (down 42.33% YoY), while the FY2025 annual figure was $95.7 million, down 10.8% from the prior year.
- Research & Development eased to $17.1 million in Q1 2026 per IPSC's latest filing, from $19.7 million in the prior quarter.
- Across five years, Research & Development topped out at $29.4 million in Q4 2024 and bottomed at $12000.0 in Q3 2025.
- Historically, Research & Development has averaged $22.8 million across 5 years, with a median of $24.5 million in 2022.
- Annual changes were most pronounced in 2022 — Research & Development soared 37.87% — and 2025, when it slumped 99.96%.
- Century Therapeutics' Research & Development stood at $25.6 million in 2022, then slipped by 12.86% to $22.3 million in 2023, then surged by 31.75% to $29.4 million in 2024, then slumped by 32.95% to $19.7 million in 2025, then retreated by 13.15% to $17.1 million in 2026.
- Business Quant data shows IPSC's Research & Development at $17.1 million in Q1 2026, $19.7 million in Q4 2025, and $12000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | 19.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.60 Mn |
| Mar 31, 2026 | 17.11 Mn |
| Dec 31, 2025 | 19.70 Mn |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 26.86 Mn |
| Mar 31, 2025 | 26.58 Mn |
| Dec 31, 2024 | 29.38 Mn |
| Sep 30, 2024 | 27.23 Mn |
| Jun 30, 2024 | 27.22 Mn |
| Mar 31, 2024 | 23.42 Mn |
| Dec 31, 2023 | 22.30 Mn |
| Sep 30, 2023 | 22.79 Mn |
| Jun 30, 2023 | 22.73 Mn |
| Mar 31, 2023 | 24.90 Mn |
| Dec 31, 2022 | 25.59 Mn |
| Sep 30, 2022 | 25.90 Mn |
| Jun 30, 2022 | 24.49 Mn |
| Mar 31, 2022 | 21.20 Mn |
| Dec 31, 2021 | 21.80 Mn |
| Sep 30, 2021 | 19.55 Mn |